DTN Launches Industry-First Operational Decisioning Platform to Transform How Businesses Compete in a Volatile World
Article content
Breakthrough platform combines vertical-specific intelligence, Decision-Grade Data, and operational AI to drive smarter, faster decisions at scale.
Article content
MINNEAPOLIS — DTN, the global leader in operational decisioning for energy, agriculture, and weather-driven industries, today announced the launch of its Operational Decisioning Platform, a new class of enterprise technology designed to help companies protect margins, reduce risk, and grow faster through better decision-making.
Article content
The current era, defined by supply shocks, extreme weather, and volatile markets, is creating a competitive divide between traditional operators and a new class of decision-ready leaders. According to a recent PwC survey, 42% of CEOs believe their companies won't survive the next decade without reinvention; the key barrier: weak decision-making processes.
Article content
The DTN Operational Decisioning Platform introduces a new class of capability. It combines sector-specific hubs, proprietary real-time data, and operational AI to deliver actionable intelligence precisely when and where it's needed.
Article content
'This platform gives operational leaders the clarity, speed, and confidence to act no matter the level of volatility,' said Patrick Schneidau, Chief Executive Officer at DTN. 'We're helping our customers turn complexity into competitive advantage.'
Article content
At the core of the platform are three sector-specific hubs, engineered around the critical workflows of DTN customers:
Article content
DTN Ag Hub
Article content
DTN Ag Hub offers a real-time digital twin of modern agriculture, integrating intelligence from inputs to producers, traders, and CPGs. With data on 95% of U.S. farms and access to validated cash bids and carbon scoring, the platform empowers smarter pricing, inventory, and sustainability decisions—driving margin and resilience across the agriculture value chain.
Article content
DTN Fuel Operations Hub
Article content
DTN manages 85% of the North American supply chain pricing and billing transactions every day. The DTN Fuel Operations Hub connects sellers, buyers, terminal operators, and traders with real-time insights across logistics and inventory. Embedded AI models and closed-loop workflows enable teams to predict market shifts, manage risk, and improve margins—at the speed of business.
Article content
DTN Weather Hub
Article content
The DTN Weather Hub delivers hyper-local forecasting, risk modeling, and compliance reporting tailored to the needs of aviation, utilities, and logistics. With data from 70,000+ sensors and 180+ meteorologists, it translates complex conditions into confident action.
Article content
'This is the most advanced weather platform I've seen—combining depth, speed, and clarity in a way that only DTN delivers,' Aaron Schellinger, Director of Event Safety at Danny Wimmer Presents, said. 'In live events, every decision impacts our crews, artists, and fans. This platform and the meteorologists at DTN give us the confidence to act decisively, knowing we're backed by the best data available.'
Article content
The launch reflects the broader evolution of DTN as a company centered around a sharpened focus on helping operational executives succeed amid growing uncertainty. Its new positioning emphasizes the need for faster, smarter decisioning at scale delivered through purpose-built platforms, Decision-Grade Data, and trusted neutrality.
Article content
'For more than 40 years, DTN has supported the companies that feed, fuel, and protect the world,' Schneidau said. 'As they face a new era of operational complexity, we remain committed to helping them make faster, smarter decisions—when and where it matters most.'
Article content
DTN is a global data and technology company that equips operational leaders in energy, agriculture, and weather-driven industries with the decision speed and intelligence to outpace uncertainty. Our Operational Decisioning Platform combines proprietary data, purpose-built vertical hubs, and operational AI to help customers expand margins, accelerate growth, and manage risk with confidence. With more than 1,200 employees across North America, Europe, and Asia Pacific, DTN proudly supports the industries that feed, fuel, and protect the world. Learn more at www.dtn.com.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
2025 AI Expo Opens in Suzhou, Highlighting Innovation in AI Industry Development
SUZHOU, China, July 28, 2025 /CNW/ -- The 7 th AI Product & Application Expo ("2025 AI Expo"), organized by the New Generation AI Industry Technology Innovation Strategic Alliance (AITISA), opened today in Suzhou. This year's event focused on high-impact themes including embodied intelligence, digital transformation, and industrial AI. A full slate of exhibitions, forums, and matchmaking sessions was held to foster industry collaboration, accelerate technical breakthroughs, and enable cross-sector innovation—shaping conversations around the trajectory of AI and the evolving contours of the industry. At the opening ceremony, three industry-defining reports were released: the Annual Report on New Generation AI Development (2024–2025), the China Urban AI Development Index Report (2024–2025), and the AI Industry Investment Trends and Development Report. These publications provide key benchmarks for tracking the progress of China's AI ecosystem. The Expo also hosted a recognition ceremony for the 2025 AI Technology Leadership Talent Settlement Projects and presented awards for the 3rd AI Product & Application Innovation and Entrepreneurship Competition and the 2nd Zu Chongzhi Award for Frontier Innovation in Artificial Intelligence. More than 20 high-profile product launches were unveiled at the new release showcase. The Expo also introduced a new "Black Tech" experience zone, where over 20 companies presented more than 200 cutting-edge technologies in an immersive demonstration space. The zone included on-site purchasing options, linking forward-looking innovation with real-world consumer engagement. To strengthen regional integration, the event expanded collaboration with Shanghai's World Artificial Intelligence Conference (WAIC), promoting talent exchange, scenario-based deployment, and shared resource strategies across the Yangtze River Delta—reinforcing Suzhou's role as a national model for AI+ application deployment. Suzhou Industrial Park, the city's engine of AI innovation, has played a leading role in advancing AI and digital industries since 2017. From the ground up, it has built an ecosystem for AI R&D, pilot applications, and industrial clustering. In recent years, the park has stepped up its "AI+" strategy, targeting next-wave technologies such as foundation models and embodied AI. It now hosts multiple national research centers and innovation platforms, and has attracted leading AI companies from China and abroad. As AI becomes more deeply embedded in the real economy, the park is driving the emergence of an AI-powered industrial cluster valued at over 100 billion yuan.
The Market Online
8 hours ago
- The Market Online
Why Celestica stock has been on a tear as of late
Celestica is a technology leader in design, manufacturing, hardware and supply chain solutions with a global presence spanning North America, Europe and Asia, and a client roster featuring some of the world's biggest brands The company's growing role as a data centre service provider has propelled revenue and profits higher since ChatGPT hit the scene in 2022 Celestica stock has soared in response, adding more than 1,700 per cent When OpenAI launched ChatGPT in 2022, it unleashed a global wave of interest and capital into artificial intelligence (AI), with companies across the industry spectrum scrambling to increase computing power and develop AI models to reach newfound levels of operational efficiency. This content has been prepared as part of a partnership with Celestica Inc., and is intended for informational purposes only. This frenzy has attracted some of the largest companies in the world, including Amazon, Alphabet and Meta, propelling each of them to multi-trillion-dollar market capitalizations, with Alphabet estimating that it will spend US$85 billion in 2025 on computing and AI to compete on the leading edge of data processing power. AI demand has also been favorable to picks-and-shovels players that have proven themselves to be reliable suppliers for the data centers developers need to test and deploy their projects. As a result, investors have candidates for due diligence for days, with US Money News and Yahoo! Finance hosting the most-viewed lists of prospective stocks on Google as of July 29. One supplier both fail to mention, Celestica (TSX:CLS), market capitalization C$32.16 billion, Canada's third-largest technology company, is a model for how strategic industry alignment can translate into shareholder value, with the stock having added more than 100 per cent year-to-date, more than 300 per cent year-over-year and more than 1,700 per cent since ChatGPT's debut, thanks to: Pre-ChatGPT data centre servicing contracts with Amazon, Alphabet and Meta. Margin expansion thanks to a shift towards proprietary products, following the arrival of chief executive officer Rob Mionis in 2015, with 43 per cent of its current line designed in house. A diversified client base across aerospace and defense, communications, enterprise, health technology, industrial and capital equipment. A turnkey service offering, from design to manufacturing to hardware platforms to supply chain solutions and full-scale production. The fact that AI, nascent as it may be, is delivering tangible value to companies across the board, saving time and resources, differentiating value propositions and pushing stock prices higher. Celestica has parlayed its prime position into impressive financials over the period, generating US$7.96 billion in revenue in 2023 and US$9.64 billion in 2024, backed up by net income of US$244.4 million and US$428 million, respectively, driven by rapidly accelerating demand. Q1 and Q2 2025 have been similarly value-accretive, delivering US$2.65 billion and US$2.89 billion in revenue, coupled with net income of US$86.2 million and US$211 million, respectively, with a robust demand outlook prompting the company to increase 2025 guidance twice over the period. The company expects to generate US$11.55 billion in revenue for the year, up from US$10.85 billion, and non-GAAP adjusted earnings per share of US$5.50, up from US$5. Celestica is further differentiated by pricing power. As confirmed in the Q2 news release, the company is positioned to recover almost all tariffs paid under US President Trump's regime from its customers, with no expected material impact to non-GAAP adjusted operating earnings or non-GAAP adjusted net earnings, demonstrating the insatiable demand for AI functionality running its way through every imaginable market. As Mionis put it in the Q2 earnings call, 'we continue to anticipate another year of solid financial performance for Celestica in 2025,' remaining 'confident in our ability to continue our strong momentum, even with the uncertainty in the current macro environment,' adding that 'we believe we are positioned to continue to excel and to sustain this positive momentum into 2026 and over the long term.' Given the multi-year upside potential at play with Celestica, investors have a chance to buy into what may prove to be a value price, despite what the company's share price of C$277.95 and price-to-earnings ratio of 46.5 may suggest at first glance. Join the discussion: Find out what investors are saying about this AI stock on the Celestica Inc. Bullboard, and make sure to explore the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Cision Canada
10 hours ago
- Cision Canada
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
VANCOUVER, BC, July 29, 2025 /CNW/ -- Equity Insider News Commentary – There's a lot of big voices pushing for the AI revolution to make its mark, including a new plan from the U.S. Department of Commerce to address slow-to-adopt sectors like healthcare. The comes as part of US President Trump's paper, titled Winning the Race: AMERICA'S AI ACTION PLAN, which encourages setting up regulatory sandboxes, or regulation-free environments where AI can be tested in real world scenarios with heavy oversight. As the market evaluates the opportunities available, several tech and biotech companies are already moving towards major milestones in AI-powered healthcare solutions, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Healthcare Triangle, Inc. (NASDAQ: HCTI), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and Spectral AI, Inc. (NASDAQ: MDAI). According to Accenture, AI could inject an additional $461 billion into the healthcare sector by 2035, as it surpasses the $2.26 trillion mark. Now, as AI makes its move into the healthcare space, experts are working to help guide these new solutions towards being more accurate, in a space where AI's inaccuracies (known as "hallucinations") are not an option. Thankfully, there are several players making important advancements in diagnostics, drug development, and workflow, through the use of AI. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have taken a key regulatory step forward by finalizing an updated clinical trial protocol for their AI-powered Vision AI platform, following formal feedback from a mid-July pre-submission meeting with the FDA. The revised protocol, which addresses the FDA's comments, has now been presented to Fortrea, the company's contract research organization, for review. Once approved, the protocol will enable the launch of a new U.S.-based clinical trial designed to support Ainnova's goal of obtaining FDA 510(k) clearance for Vision AI in the early detection of diabetic retinopathy. "We are committed to meeting the highest regulatory standards, and we're confident that these protocol refinements will strengthen our path toward FDA 510(k) clearance," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We anticipate finalizing the clinical trial budget soon, with estimated costs coming more into focus as we refine our protocol and navigate the process." The U.S. regulatory push builds on expanding visibility for Vision AI across Latin America. In June, Vargas was featured at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent diabetic blindness and improve health access in low-resource settings. He also highlighted a Q4 2024 pilot with Roche and Salud 360 that could scale across the U.S., Canada, and Europe if successful. Meanwhile, Vision AI has gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offering walk-in screenings, real-time AI results, and direct referrals to care providers. The model eliminates the need for onsite ophthalmologists and is gaining traction with pharmacy chains, insurers, and life sciences partners. Avant and Ainnova's FDA engagement follows an earlier pre-submission meeting in July, where the agency provided clear guidance on study design and compliance. The refined clinical trial protocol, once greenlit, will guide a formal U.S. study aimed at supporting FDA clearance to market Vision AI domestically. Avant maintains global licensing rights to Ainnova's platform through Ai-nova Acquisition Corp., the JV established to commercialize Ainnova's technology portfolio. U.S. entry is viewed as a major inflection point with significant commercial potential. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. Avant has also signaled plans for a dedicated therapeutic-focused spinout and continues to evaluate a full acquisition of Ainnova Tech under a previously announced non-binding LOI—potentially consolidating all assets and leadership under a single public platform. Renovaro Inc. (NASDAQ: RENB) secured multiple U.S. patents for its federated AI learning technologies in biomedical research. "Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine," said David Weinstein, CEO, Renovaro. These patents support secure, privacy-preserving data integration across hospitals and labs for applications in drug discovery and precision medicine. The move strengthens Renovaro's position in the $20 billion biomedical AI space. Healthcare Triangle, Inc. (NASDAQ: HCTI) recently signed major contracts with large U.S. hospital systems and expanded its AI-powered EHR services. Its platform converts unstructured medical documents into usable data for clinicians. "These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision," said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle." We're driving digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider." The company is focused on making EHR systems smarter, more efficient, and better suited to community health networks. GE HealthCare Technologies Inc. (NASDAQ: GEHC) launched its Definium Pace Select ET, an AI-powered digital X-ray system for high-volume medical settings. "This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps," said Jyoti Gupta, PhD, President and CEO of Women's Health and X-ray at GE HealthCare. "We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging." The system automates repetitive tasks and improves image consistency to help radiologists work more efficiently. It's designed to relieve staffing pressures while maintaining high imaging standards in busy hospitals. Spectral AI, Inc. (NASDAQ: MDAI) submitted its DeepView System to the FDA for marketing approval under the De Novo pathway. "This FDA submission is a major milestone for Spectral AI and the DeepView System, representing a crucial step toward bringing this innovative diagnostic device to market in the United States," said Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. "It provides clinicians with an immediate, data-driven assessment tool designed to assist clinical decision-making and may significantly improve patient outcomes." The device uses multispectral imaging and AI to predict how burn wounds will heal, helping doctors make faster and more accurate treatment decisions. It's positioned as a first-of-its-kind diagnostic tool in burn care. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
